EPIRUBICIN HYDROCHLORIDE INJECTION Strength
Active ingredient(s) See footnote 8 : Strength EPIRUBICIN HYDROCHLORIDE : 2 MG / ML · DIN 02303892 · ACCORD HEALTHCARE INC 3535 Boulevard St-Charles, Suite 704 Kirkland Quebec Canada H9H 5B9
Health Canada status: CANCELLED POST MARKET
What is EPIRUBICIN HYDROCHLORIDE INJECTION?
EPIRUBICIN HYDROCHLORIDE INJECTION Strength contains Active ingredient(s) See footnote 8 : Strength EPIRUBICIN HYDROCHLORIDE : 2 MG / ML. It is listed in the Health Canada Drug Product Database under DIN 02303892, held by ACCORD HEALTHCARE INC 3535 Boulevard St-Charles, Suite 704 Kirkland Quebec Canada H9H 5B9, supplied as Solution for Intravenous administration. Health Canada currently lists it as cancelled post market, status dated 03-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EPIRUBICIN HYDROCHLORIDE INJECTION used for?
Metastatic breast cancer, adjuvant treatment of early stage breast cancer, small cell lung cancer, non-small cell lung cancer, lymphomas, ovarian carcinoma, and gastric carcinoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02303892 |
|---|---|
| Brand name | EPIRUBICIN HYDROCHLORIDE INJECTION |
| Generic / active ingredient | Active ingredient(s) See footnote 8 : Strength EPIRUBICIN HYDROCHLORIDE : 2 MG / ML |
| Manufacturer | ACCORD HEALTHCARE INC 3535 Boulevard St-Charles, Suite 704 Kirkland Quebec Canada H9H 5B9 |
| Strength | Strength |
| Dosage form | Solution |
| Route of administration | Intravenous |
| Schedule | PRESCRIPTION |
| ATC code | L01DB03 EPIRUBICIN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 03-Oct-2012 |
| Original market date | 2008-11-28 |
How is it administered?
Administered intravenously. Dosage depends on tumor type and regimen. Cumulative dose of 900-1000 mg/m2 should generally not be exceeded. Requires close hematologic and cardiac monitoring.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).
Contraindications
Hypersensitivity to epirubicin/anthracyclines; marked persistent myelosuppression; severe hepatic impairment; severe myocardial insufficiency; recent MI; severe arrhythmias; max cumulative doses.
Warnings and precautions
Potent drug; risk of irreversible cardiac toxicity and secondary AML/MDS. Severe local tissue necrosis if extravasated. Myelosuppression is common. Monitor LVEF and blood counts.
Is EPIRUBICIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 17 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01DB03 EPIRUBICIN. 1 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EPIRUBICIN FOR INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02324091 |
| EPIRUBICIN HYDROCHLORIDE FOR INJECTION | Strength | Powder For Solution | HOSPIRA HEALTHCARE ULC 17300 Trans-Canada Highway Kirkland Quebec Canada H9J 2M5 | CANCELLED POST MARKET | DIN 02301067 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02413221 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02264927 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | UMAN PHARMA INC | APPROVED | DIN 02322242 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED PRE MARKET | DIN 02323001 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02387379 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | OMEGA LABORATORIES LIMITED | APPROVED | DIN 02409372 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2.0 MG | SOLUTION | FRESENIUS KABI CANADA LTD | DORMANT | DIN 02312093 |
| PHARMORUBICIN PFS | 2 MG | SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02065703 |
Who else supplies EPIRUBICIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EPIRUBICIN appears in 46 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.